open access: Cancer treatment and care: a new and uneasy world : The Lancet

"......Thinking of the future, we sense oncological needs and expectations growing beyond what can be planned or provided for fairly. A drug like abiraterone, promising benefit in an area of evident clinical need, will have taken 20 years and substantial funds to develop. Early stage drug development is likely to have been undertaken by researchers with charitable or public funding, with the translational and clinical research by commercial entities leading, in abiraterone's case, to indelicate public haggling over how much 1 year of an average patient's life is reasonably worth....."